Hepatitis E - Treatment.
Racial Disparities in Hepatitis C Treatment Eligibility
8
Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review
12
Module VPredictive factors for response to treatment of chronic hepatitis C
5
Treatment with Metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis
10
Does hepatitis B virus coinfection have any impact on treatment outcome in hepatitis C patients on hemodialysis?
8
Genomic determinants of hepatitis C virus antiviral therapy outcomes: toward individualized treatment
11
Effects of Age on Treatment of Chronic Hepatitis C with Direct Acting Antivirals
10
Meta Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection
15
Mycobacterium abscessus pulmonary infection during hepatitis C treatment with telaprevir, peginterferon and ribavirin
5
First successful treatment of post liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre transplant null responder
5
Current concepts in the management and treatment of hepatitis C in HIV infected patients
11
New approaches and therapeutic modalities for the treatment of patients with chronic hepatitis C
8
Chronic Hepatitis C Treatment with Direct Acting Antiviral Agents in a Real Life Setting
9
Early treatment with N acetylcysteine in children with acute liver failure secondary to hepatitis A
6
Effects of a multidisciplinary approach on the effectiveness of antiviral treatment for chronic hepatitis C
8
Pulmonary complications of treatment with pegylated interferon for hepatitis C infection Two case reports
5
Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection
166
Outcome of early vs deferred antiviral treatment for recurrent hepatitis C in liver transplant recipients
12
Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir Containing Hepatitis C Virus Treatment
6
Module XlXCost efficacy and costbenefit of treatment of hepatitis C
5